Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study.

ABSTRACT:

Background

Integrase strand-transfer inhibitors (INSTI) are a key part of contemporary antiretroviral therapy (ART). Raltegravir (RAL) was the first INSTI and remains recommended for some people with HIV. We investigated all-cause mortality between RAL-based ART and other INSTIs in the RESPOND cohort consortium among both ART-naïve and treatment experienced individuals.

Methods

RESPOND, a multicenter prospective cohort study, includes approximately 40,000 adults (≥18 years) with HIV from 17 cohorts across Europe and Australia. Individuals eligible for inclusion into RESPOND had ≥1 clinical visit at a site participating in RESPOND after January 01, 2012, and a CD4 count and HIV viral load measurement available at inclusion. Participants in RESPOND who started their first INST

SUBMITTER: Tusch E 

PROVIDER: S-EPMC12495419 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature